Table 1. Safety overview Event, N (%) .... | American Society of Hematology

Table 1.

Safety overview

Event, N (%)	All patients (N=14)
Any grade TEAE∗	14 (100)
Grade 3/4 TEAE	10 (71.4)
SAE	8 (57.1)
Venetoclax-related TEAE	10 (71.4)
Ibrutinib-related TEAE	13 (92.9)
AE leading to venetoclax interruption	9 (64.3)
AE leading to venetoclax reduction	2 (14.3)
AE leading to venetoclax discontinuation excluding progression†	1 (7.1)
AE leading to ibrutinib interruption	10 (71.4)
AE leading to ibrutinib reduction	1 (7.1)
AE leading to ibrutinib discontinuation excluding progression†	1 (7.1)
AE leading to death	5 (35.7)
Death	10 (71.4)

Event, N (%)	All patients (N=14)
Any grade TEAE∗	14 (100)
Grade 3/4 TEAE	10 (71.4)
SAE	8 (57.1)
Venetoclax-related TEAE	10 (71.4)
Ibrutinib-related TEAE	13 (92.9)
AE leading to venetoclax interruption	9 (64.3)
AE leading to venetoclax reduction	2 (14.3)
AE leading to venetoclax discontinuation excluding progression†	1 (7.1)
AE leading to ibrutinib interruption	10 (71.4)
AE leading to ibrutinib reduction	1 (7.1)
AE leading to ibrutinib discontinuation excluding progression†	1 (7.1)
AE leading to death	5 (35.7)
Death	10 (71.4)

AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

TEAE was defined as any event with onset after the first does of study drug to no more than 30 days after the first dose of study drug.

Events that had PD as a reason for study drug discontinuation were excluded.